Cabozantinib for previously treated radioiodine‐refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC‐311 trial

BACKGROUND: At an interim analysis (median follow‐up, 6.2 months; n = 187), the phase 3 COSMIC‐311 trial met the primary end point of progression‐free survival (PFS): cabozantinib improved PFS versus a placebo (median, not reached vs. 1.9 months; p < .0001) in patients with previously treated rad...

Descripción completa

Detalles Bibliográficos
Autores principales: Brose, Marcia S., Robinson, Bruce G., Sherman, Steven I., Jarzab, Barbara, Lin, Chia‐Chi, Vaisman, Fernanda, Hoff, Ana O., Hitre, Erika, Bowles, Daniel W., Sen, Suvajit, Oliver, Jennifer W., Banerjee, Kamalika, Keam, Bhumsuk, Capdevila, Jaume
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092751/
https://www.ncbi.nlm.nih.gov/pubmed/36259380
http://dx.doi.org/10.1002/cncr.34493

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092751/
https://www.ncbi.nlm.nih.gov/pubmed/36259380
http://dx.doi.org/10.1002/cncr.34493

Ejemplares similares